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Abstract: The question of whether a newly identified sequence variant is truly a causative mutation
is a central problem of modern clinical genetics. In the current era of massive sequencing, there is
an urgent need to develop new tools for assessing the pathogenic effect of new sequence variants.
In Charcot-Marie-Tooth disorders (CMT) with their extreme genetic heterogeneity and relatively
homogenous clinical presentation, addressing the pathogenic effect of rare sequence variants within
80 CMT genes is extremely challenging. The presence of multiple rare sequence variants within
a single CMT-affected patient makes selection for the strongest one, the truly causative mutation,
a challenging issue. In the present study we propose a new yeast-based model to evaluate the
pathogenic effect of rare sequence variants found within the one of the CMT-associated genes, GDAP1.
In our approach, the wild-type and pathogenic variants of human GDAP1 gene were expressed in
yeast. Then, a growth rate and mitochondrial morphology and function of GDAP1-expressing strains
were studied. Also, the mutant GDAP1 proteins localization and functionality were assessed in yeast.
We have shown, that GDAP1 was not only stably expressed but also functional in yeast cell, as it
influenced morphology and function of mitochondria and altered the growth of a mutant yeast strain.
What is more, the various GDAP1 pathogenic sequence variants caused the specific for them effect in
the tests we performed. Thus, the proposed model is suitable for validating the pathogenic effect
of known GDAP1 mutations and may be used for testing of unknown sequence variants found in
CMT patients.
Keywords: yeast; mitochondria; Charcot-Marie-Tooth type 4 disease; GDAP1 gene; GDAP1 gene
mutations
1. Introduction
In the past, molecular genetic testing was limited to single genes. Nowadays, whole exome
sequencing (WES) is applied, the result of which is a series of DNA sequence variants even for the
Mendelian diseases [1]. For example, in the hereditary peripheral neuropathies (Charcot-Marie-Tooth
disorders; CMT) categorized as monogenic disorders (more than 80 genes involved), nearly 30% of the
patients harbor two rare sequence and ten percent patients have three rare sequence variants in the
CMT genes [2].
In Charcot-Marie-Tooth type 4A disease (CMT4A), causative mutations were identified in GDAP1
(ganglioside induced differentiation associated protein 1) [3,4]. The role of the GDAP1 gene in the
physiology and pathology of the peripheral nerves is still not deciphered [5,6]. Recessive and dominant
mutations within the GDAP1 gene segregate with severe and moderate to mild clinical progressions of
the disease, respectively [7,8].
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It appears that the pathogenic effect of the GDAP1 gene sequence variants reported until now
varies substantially. However, different mutations were investigated in different manners. For some
(causing Leu239Phe, Gly327Asp), the pathogenic effect has been documented by functional studies,
whereas other characteristics are limited to clinical and electrophysiological observations. In addition,
objective evaluation of the strength of any given mutation is hampered by the degree of mutation
prevalence, which varies widely, i.e. some of the GDAP1 gene mutations were reported in numerous
CMT families (Glu163X, Ser194X), whereas others (His123Arg, Glu222Lys) were reported in small and
even single pedigrees [6].
Initially, the GDAP1 gene was identified as being induced upon enhanced ganglioside
production [9]. Later it was shown that GDAP1 is a mitochondrial membrane protein mainly present
in neuronal cells [10–12]. It is involved in mitochondria fission [13,14], calcium homeostasis [15,16],
and maintenance of cellular redox potential [17,18], although the exact function of GDAP1 in these
processes is unknown.
In yeast there is no simple homolog of human GDAP1 gene, however it was shown that it
complements some FIS1 gene deletion phenotypes, coding for protein involved in mitochondrial
fission process [19]. These results suggest that GDAP1 is functional in yeast cells and possesses
molecular partners.
The aim of this study was to develop a reproducible yeast-based system for determination of the
pathogenicity of GDAP1 sequence variants. This system is based on the mitochondrial localization
of GDAP1 protein and its mutations influence on mitochondria morphology and calcium signaling
in mammalian cells. Here, we studied a localization of mutant GDAP1 proteins in yeast cells, its
impact on mitochondrial network formation, the rate of mitochondrial DNA escape to the nucleus and
the ability to grow on a non-fermentable carbon source. Additionally, we found that expression of
wild-type GDAP1 gene reduces the growth defects of the yeast csg2∆mutant, with the deletion of a gene
required for mannosylation of inositolphosphorylceramide, while mutated versions of GDAP1 do not.
In summary, our model may help to identify potentially pathogenic GDAP1 alleles in CMT patients.
2. Materials and Methods
2.1. Strains, Media, and Growth Conditions
Escherichia coli strains DH5α and XL1-Blue were used for plasmid propagation. The yeast
Saccharomyces cerevisiae strains used in this study were BY4741 MATa his3∆1 leu2∆0 met15∆0 ura3∆0,
BY4741 csg2∆ and PTY44 MATα ura3-52 lys2 leu2-3,112 trp1∆1 [rho+, TRP1] [20].
Yeast were grown at 28 ◦C or 30 ◦C in YPD medium (1% yeast extract, 2% peptone, 2% glucose),
YPG medium (1% yeast extract, 2% peptone, 3% glycerol) or YPG + 0.2% glucose, in minimal synthetic
medium with glycerol (0.67% yeast nitrogen base with ammonium sulfate without amino acids,
3% glycerol with desired supplements (uracil, amino acids)) or in complete synthetic medium (SC)
(0.67% yeast nitrogen base with ammonium sulfate without amino acids, 2% glucose or 3% glycerol
with complete supplement mixture (CSM-ade-his-leu-trp-ura)) either solid or liquid. For growth
tests, mitochondrial observations and mitochondrial DNA escape assays, a mixture of several yeast
colonies, obtained after transformation, were grown overnight in liquid media. For growth tests
the optical cell density (OD600) was determined and cultures were diluted with water to OD600 ∼1.
Subsequently, aliquots of 10-fold serial dilutions of cells were spotted on solid media plates (as
indicated) supplemented as indicated. Plates were incubated at 28 ◦C for the indicated number of days.
2.2. Plasmids
The plasmids used in this study are listed in Table 1.
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Table 1. Plasmid used in this study.
Plasmid Source or Reference
pCMV6-XL5-GDAP1 OriGene
p425-PTDH3 [2µ; LEU2] [21]
p425-PTDH3-GDAP1 This study
p425-PTDH3-GDAP1m1 This study
p425-PTDH3-GDAP1m2 This study
p425-PTDH3-GDAP1m3 This study
p425-PTDH3-GDAP1m4 This study
p425-PTDH3-GDAP1m5 This study
p425-PTDH3-GDAP1m6 This study
p425-PTDH3-GDAP1m7 This study
p425-PTDH3-GDAP1m8 This study
PXY122 (mt-GFP) [2µ, HIS3] [22]
The p425-PTDH3-GDAP1 and p425-PTDH3-GDAP1m1 plasmids were produced by amplification of
full length or truncated GDAP1 cDNA by PCR using a commercially available pCMV6-XL5 vector
containing cDNA of GDAP1 (NM_018972; OriGene) as a template and primers providing restriction
sites (BamHI at 5’-end and SalI 3’-end) and additional codon stop for GDAP1 m1 and ligation obtained
alleles into p425-PTDH3 vector. The m2 (c.980G>A; p.Gly327Asp), m3 (c.652C>G; p.Gln218Glu), m4
(c.664G>A; p.Glu222Lys), m5 (c.715C>T; p.Leu239Phe), m6 (c.368A>G; p.His123Arg), m7 (c.347T>C;
p.Met116Thr), and m8 (c.467C>G; p.Ala156Gly) mutations were introduced by site directed mutagenesis
into cDNA GDAP1 gene.
2.3. Site Directed Mutagenesis
Site directed mutagenesis was performed on the OriGene plasmid: pCMV6-XL5 with GDAP1
(NM_018972) Human Untagged Clone, using the Mut Express II Fast Mutagenesis Kit V2 (Vazyme) in
accordance with the manufacturer’s instructions.
Primers for mutagenesis were designed using Quick Change Primer Design (Agilent) on-line
software (the primer sequences were placed in Table A1).
Escherichia coli strain XL1-Blue was used for plasmid propagation. The presence of mutations
within constructed plasmids was verified by the Sanger sequencing method.
2.4. Fluorescence Microscopy
Mitochondria morphology was observed in yeast cells grown overnight in SC-leu-his media
at 30 ◦C and transferred into SC gly-leu-his for 4 h. The cells were viewed with an Eclipse E800
(Nikon, Tokyo, Japan) fluorescence microscope equipped with a DS-5Mc camera (Nikon). Images were
collected using Lucia General 5.1 software (Laboratory Imaging Ltd., Prague, Czech Republic). The
same fields were viewed by differential interference contrast (DIC) optics.
2.5. Confocal Microscopy
To observe the localization of GDAP1, yeast cells were grown overnight in SC-leu-his media
at 28 ◦C and shifted into SC gly-leu-his for 4 h. Cells were fixed by incubation for 25 min in 3.7%
formaldehyde. They were collected by centrifugation and washed four times in buffer B (40 mM
potassium phosphate, pH 7.0; 0.5 mM MgCl2; 1.2 M sorbitol). Then they were resuspended in buffer B
supplemented with 0.2 mg/mL Zymolyase 20T (Amsbio, Abingdon, UK) and 1% 2-mercaptoethanol
and incubated for 1 h at 37 ◦C. The resulting spheroplasts were washed twice in buffer B and were
spotted onto polylysine-coated slides. They were permeabilized by incubation in buffer F (20 mM
potassium phosphate, pH 7.4; 150 mM NaCl; 0.1% BSA) supplemented with 0.1% Triton-X-100 for
15 min. The slides were rinse with buffer F and saturated in buffer F for 1 h. Then they were incubated
with rabbit polyclonal anti-GDAP1 antibody (Abcam, Cambridge, MA, USA) diluted 1:200 in buffer F
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for 2 h. They were washed with buffer F and incubated with TRITC-conjugated porc anti-rabbit IgG
antibody (DAKO, Agilent, Santa Clara, CA, USA) diluted 1:60 for 2 h. Then slides were rinsed with
buffer F and nucleus was stained by DAPI (Thermo Fisher Scientific, Waltham, MA, USA) for 2 min.
After being washed with water, slides were mounted in mounting medium (DAKO). Samples were
viewed using LSM 780 Axio Observer Z.1 confocal microscope (Zeiss, Oberkochen, Germany). Images
were collected using Zen 2012 black edition software (Zeiss). The confocal microscopy observations
were performed in Laboratory of Advanced Microscopy Techniques, Mossakowski Medical Research
Centre, PAS.
2.6. Western Blot Analysis
Yeast cells were grown overnight at 28 ◦C in SC -leu medium. Protein extracts were prepared
after disrupting cells with acid-washed glass beads in 2 × urea electrophoresis sample buffer
(50 mM Tris-HCl pH 6.8; 1.6% SDS; 7% glycerol; 0.016% bromophenol blue; 4% β-mercaptoethanol;
8M urea) supplemented with protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MI, USA).
Samples were analyzed by standard Western blotting using rabbit polyclonal anti-GDAP1 (Abcam)
or rabbit polyclonal anti-Histone H3 (Abcam) antibodies and secondary anti-rabbit IgG horseradish
peroxidase (HRP)-conjugated antibodies (Sigma-Aldrich), followed by enhanced chemiluminescence
(GE Healthcare, Boston, MA, USA).
2.7. DNA Escape Assay
DNA escape from mitochondria to the nucleus was assayed as in [20]. Briefly, the PTY44 strain
was transformed with empty vector or one of the vectors bearing cDNA of GDAP1 variants. The
transformants were grown in minimal synthetic medium with glycerol-leu overnight and aliquots
were spread on SC-trp or diluted and spread on YPD to count colony forming units. The percentage of
cells able to grow on SC–trp was calculated for each type of transformants.
2.8. Estimation of Yeast Respiratory-Deficiency
Cells were grown overnight in YPG medium, diluted, and spread on a medium containing glycerol
(non-fermentable) as the main source of carbon and with a limited amount of fermentable glucose
(0.2%). We counted the fraction of small colonies (the respiratory deficient) whose growth was limited
due to reduced levels of available fermentable glucose in relation to the total number of colonies.
3. Results
3.1. Selection of GDAP1 Mutations
From over 100 GDAP1 gene sequence variants, we have selected the eight most representative
for CMT4A disease in the Polish families diagnosed and observed for at least 5 years in the Warsaw
Neuromuscular Unit (clinical electrophysiological and morphological studies have been previously
reported). The main selection criterion was our detailed knowledge of the phenotypes associated with
each mutation that have been extensively characterized in our laboratory [23–26]. We refer to our
selected mutations as GDAP1 m1 to m8 (Figure 1). Three mutations cause amino acid substitutions:
Gly327Asp (m2), Leu239Phe (m5), and Met116Thr (m7), and belong to the class of mutations inherited
as an autosomal recessive trait. The mutations Gly218Glu (m3), Ala156Gly (m8), and His123Arg
(m6) represent pure dominant GDAP1 gene mutations. It was shown that the GDAP1 m4 mutation
(Glu222Lys) is inherited in both dominant and recessive ways. The last mutation, that we called
GDAP1 m1, results in a C-terminal truncation of the GDAP1 protein (to 287 amino acid residues). This
mutation is representative for the two recurrent nonsense GDAP1 gene mutations i.e. Glu163X and
Ser194X (Figure 1).
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flagged by stars (*) and recessive instances by a hashtag (#). GDAP1 m4, which may be inherited in 
both dominant and recessive ways, is indicated by dot (•). Domains (based on Pfam database): (GST) 
glutathione S-transferase domain; (HD) hydrophobic domain; (TMD) transmembrane domain. 
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cDNA of the human wild-type GDAP1 gene, and of the GDAP1 variants, in yeast cells. First, we 
investigated the effect of GDAP1 cDNA expression on growth of the wild-type yeast cells. 
Expression of neither the wild-type GDAP1 nor any of the mutated variants (GDAP1 m1–m8) 
affected the growth of yeast cultures on rich YPD (Figure 2A). To ensure that the GDAP1 variants 
are properly expressed, the total cell extracts obtained from cells transformed with empty vector 
or bearing cDNA of GDAP1 variants were prepared, separated by SDS-PAGE and 
immunoblotted with anti-GDAP1 antibodies. As a loading control, the levels of Histone 3 were 
monitored. Bands corresponding to GDAP1 and GDAP1 m1 proteins of appropriate molecular 
weights were observed (Figure 2B). The cDNAs of the missense GDAP1 gene variants (GDAP1 
m1, m3, m4, m5, m6, m7, m8) were also stably expressed in wild-type yeast cells (Figure 2B). 
Thus, we were able to prove that in a heterologous system, human GDAP1 variants are 
expressed and that their expression does not disturb the growth of wild-type yeast cell cultures. 
Due to the lack of any noticeable difference in growth between transformants expressing the 
cDNA of wild-type GDAP1 or of its mutants, we had to search for conditions that allowed us to 
differentiate between cells producing wild-type GDAP1 and cells producing mutant GDAP1 
proteins. 
3.3. Specific GDAP1 Mutations Cause Mislocalization of the Resulting GDAP1 Protein 
GDAP1 protein was been characterized as being localized to the mitochondrial membrane in 
neuronal cells [10–12]. Thus, in order to further characterize human GDAP1 functionality in the 
heterologous yeast-based system, we analyzed its cellular localization by confocal microscopy. The 
yeast cells were transformed with a plasmid encoding a mitochondrially targeted green fluorescence 
protein (mt-GFP) [22], empty vector or a series of GDAP1 variants either with or without mutations. 
The wild-type GDAP1 protein was located in structures that matched the location of mt-GFP. 
Similarly, m3, m4, m5, m6 and m7 mutations did not result in changes in the subcellular localization 
of these GDAP1 protein variants. Two mutations, namely m1 and m2 (causing a C-terminal deletion 
and the Gly327Asp substitution, respectively), resulted in GDAP1 proteins that did not localize to 
mitochondria (Figure 2C and A1). However, the level of fluorescence signal from the GDAP1 m2 
protein was only slightly higher than the background signal observed for the empty vector control 
making it very difficult to observe the protein. The mislocalization of the GDAP1 m1 and m2 protein 
variants is most probably the result of an absence (in the case of GDAP1 m1) or functional impairment 
(for GDAP1 m2) of the transmembrane domain (TMD), which has previously been shown to be 
Figure 1. Schematic representation of the GDAP1 domain structure. Studied protein changes are
indicated. GDAP1 m1 is a truncated version of GDAP1, lacking the domains responsible for correct
localization of the protein (HD and TMD). Dominant mutations leading to the given substitution are
flagged by stars (*) and recessive instances by a hashtag (#). GDAP1 m4, which may be inherited in
both dominant and recessive ways, is indicated by dot (•). Domains (based on Pfam database): (GST)
glutathione S-transferase domain; (HD) hydrophobic domain; (TMD) transmembrane domain.
3.2. cDNA of the Human GDAP1 Gene Coding for Ganglioside Induced Differentiation Associated Protein 1 Is
Stable When Heterologously Expressed in Yeast Cells
Due to the absence of homology between human GDAP1 and any yeast gene we were unable to
apply the strategy usually used in complementation tests. To address whether we can use yeast cells
to assess the severity of the pathogenicity of GDAP1 variants, we expressed the cDNA of the human
wild-type GDAP1 gene, and of the GDAP1 variants, in yeast cells. First, we investigated the effect of
G AP1 cDNA expression on growth of the wild-type yeast cells. Expression of neither the wild-type
GDAP1 nor any of the mutated variants (GDAP1 m1–m8) affected the growth of yeast cultures on rich
YPD (Figure 2A). To ensure that the P1 variants are properly expressed, the total cell extracts
obtained from cells transformed with empty vector or bearing cDNA of GDAP1 variants were prepared,
separated by SDS-PAGE and immunoblotted with anti-GDAP1 antibodies. As a loading control, the
levels of Histone 3 were monitored. Bands corresponding to GDAP1 and GDAP1 m1 proteins of
appropriate molecular weights were observed (Figure 2B). The cDNAs of the missense GDAP1 gene
variants (GDAP1 m1, m3, m4, m5, m6, m7, m8) were also stably expressed in wild-type yeast cells
(Figure 2B). Thus, we were able to prove that in a heterologous system, human GDAP1 variants are
expressed and that their expression does not disturb the growth of wild-type yeast cell cultures. Due
to the lack of any noticeable difference in growth between transfor ants expressing the cDNA of
wild-type GDAP1 or of its mutants, we had to search for conditions that allowed us to differentiate
between cells producing wild-type GDAP1 and cells producing mutant GDAP1 proteins.
3.3. Specific GDAP1 Mutations Ca se Mislocalization of the Resulting GDAP1 Protein
GDAP1 protein was been characterized as being localized to the mitochondrial membrane in
neuronal cells [10–12]. Thus, in order to further characterize human GDAP1 functionality in the
heterologous yeast-based system, we analyzed its cellular localization by confocal microscopy. The
yeast cells were transformed with plasmid encoding a mitochondrially targeted g een fluorescence
protei (mt-GFP) [22], empty vector o a series of GDAP1 variants either with or without mutations.
The wi d-type GDAP1 protein was located in structur s that matched the location of mt-GFP. Similarly,
m3, m4, m5, m6 and m7 mutat ons did not r sult i changes in the subcellular localization of thes
GDAP1 protein variants. Two mutations, namely m1 and m2 (causing a C-terminal dele ion and the
Gly327Asp substitution, respectively), resul in GDAP1 proteins that did no localize t mitochondria
(Figures 2C and A1). However, the level of fluorescence signal from the GDAP1 m2 prote n was
nly slightly higher han the background signal observ d for the empty vector control aking it very
difficult to observe the protein. The mislocalization of the GDAP1 m1 and m2 pro ein variants is most
probably the result of an absence (in the case of GDAP1 m1) functional impair ent (for GDAP1
m2) of the transmembrane domain (TMD), which has previously b en shown to be responsible f r the
itochondrial membrane anchoring of GDAP1. Similarly to previous obs rvations ade in COS7 cells,
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mutations that resulted in changes within the TMD (e.g. GDAP1 m2) of the GDAP1 protein impaired
the targeting of GDAP1 to the mitochondrial membrane [25].
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In previous studies, GDAP1 has been shown to alter the formation of mitochondrial networks 
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the human protein is also localized to the mitochondria. The mitochondria were visualized by 
expression of mt-GFP. The network of mitochondria of cells transformed with empty vector were 
Figure 2. Yeast-based system to analyze GDAP1 protein function. (A) Overnight cultures of wild-type
yeast cells harboring empty vector ([-]) or plasmids with GDAP1 gene variants were diluted to OD600
≈ 1 and then ten-fold serial dilutions were prepared and spotted on to YPD medium. Plates were
incubated for 2 d at 28 ◦C. (B) Yeast wild-type cells harboring empty vector ([-]) or plasmids with
GDAP1 gene variants (as indicated) were cultured overnight in SC-leu at 28 ◦C, then were collected and
disrupted. The total cell extracts obtained were analyzed by SDS-PAGE, followed by immunoblotting
with anti-GDAP1 or anti-Histone H3 antibodies, as indicated. (C) Yeast wild-type cells transformed with
plasmid encoding mitochondrially targeted green fluorescent protein (mt-GFP) and with empty vector
([-]) or plasmids encoding GDAP1 alleles (as indicated) were grown in SC–leu-his medium overnight
and then were shifted to glycerol-containing medium for 4 h to induce expansion of mitochondria. Cells
were fixed, stained and observed using confocal microscopy. GDAP1 was visualized by immunostaining
(red), mitochondria using the mt-GFP protein marker (green) and the nucleus was stained with DAPI
(blue). Scale bar 5 µm.
3.4. Expression of Human GDAP1 cDNA Affects Mitochondrial Network Formation in Yeast
In previous studies, GDAP1 has been shown to alter the formation of mitochondrial networks
when expressed in HeLa cells [23]. In our study we inves igated whether expression of GDAP1 in
the heterologous syst m also changes the morphology of mitochondrial networks, especially given
that the human protein is also localized to t e mitochondria. The mitoch ndria w re visualized by
expression of mt-GFP. The network of mitochondria of cells transformed with empty vector were used
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as a reference. As expected, mitochondria formed tubular network structures below the cell cortex.
After the introduction of cDNA encoding human GDAP1 protein, we observed an alteration of the
mitochondrial network. We named this a supernetwork due to the more extensive and branched
nature of the network (Figure 3A). Compared to the wild–type yeast, about 50% of the counted GDAP1
transformed cells displayed this supernetwork phenotype. We also observed spherical and abnormal
phenotypes, but there were no marked differences in the number of cells with such mitochondria
between the cells expressing the cDNA of wild-type GDAP1 and those that were not (Figure 3A).
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3. Mitochondria functioni g is changed upon GDAP1 expression in yeast. (A) Overnight cultures
of wild-type yeast cells harboring plasmid bearing mitochondrially targeted green fluorescent prot i
(mt-GFP) and empty vector ([-]) or plasmid with full-length GDAP1 were shifted to glycerol-containing
medium for 4 h to i duce expansion of mitochondria. Mitochondrial morphology was observed
using flu rescent microscopy. The described phenotypes were counted. Error bars repres nt standar
deviation for thre independent biological experiments. (B) PTY44 strain transformed with empty
vector ([-]) or GDAP1 gene variants (as indicated) was incub ted for 2 ays in glycerol-containing
medium and then the cells wer counted, and dilutions of v ry culture were plated on YPD or SC-trp
medium. After 3 d of incubation at 28 ◦C the number of col y-forming units (CFUs) was calculated.
The fraction of SC-trp-growing cells in every culture were normalized to PTY44 with empty vector ([-]).
Error bars represent standard deviation for four experiments. (C) Wild-type yeast strain harboring
empty vectors ([-]) or plasmids with GDAP1 alleles were grown overnight in SC gly-leu medium. The
cultures were diluted, and cells were plated on YPG + 0.2% glucose and incubated for 3 d at 28 ◦C.
CFUs were counted and the percentage of small colonies was calculated. Error bars represent standard
deviation for four experiments.
We have confirmed the role of human GDAP1 protein in the formation of the mitochondrial
network in yeast cells. The phenotypes we observed, however, were not suitable to distinguish between
GDAP1 mutants or to use as a prognostic marker to assess pathogenicity of GDAP1 mutations.
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3.5. Some GDAP1 Protein Mutants When Produced in Yeast Increase the Rate of Mitochondrial DNA Escape to
the Nucleus
In the previous experiment we have shown that expression of the cDNA from the human GDAP1
gene influences the formation of the mitochondrial network in yeast. Moreover, a relationship between
mitochondrial network disturbances and mutations in the GDAP1 gene was reported [12,14]. Taking
into account that the mitochondrial network formation is directly associated with mitochondrial
biogenesis and that this process is accompanied by an exchange of mitochondrial DNA [27,28], we
decided to check the functionality of mitochondria by assessment of mtDNA escape to the nucleus [29].
Thus, we hypothesized that at least some GDAP1 gene mutations may affect mitochondrial DNA
escape; from the mitochondria to the nucleus. To measure the rate of mtDNA escape to the nucleus,
the TRP1 gene, encoding an enzyme from the tryptophan biosynthesis pathway, was integrated into
the mitochondrial genome [20,30] in a strain carrying a defective trp1 allele in the (nuclear) genome.
Such yeast is unable to grow without tryptophan supplementation. During the propagation of such
yeast, mtDNA escapes from the mitochondria to the nucleus where it integrates and complements the
defective nuclear TRP1 allele allowing cells to grow on the media without tryptophan [20,31].
The idea of this experiment may be summarized by the following simple association: more
extensive abnormal mitochondria leads to a greater rate of DNA escape and reflects the severity of the
GDAP1 gene mutation. The greatest mitochondrial DNA escape rate was observed when the cDNA of
GDAP1 m5 (resulting in the Leu239Phe substitution) was expressed (Figure 3B). A moderate effect
was observed for GDAP1 m2 (Gly327Asp substitution within the TMD). The effect of expressing other
GDAP1 variants was not strong. There were no statistically relevant differences in mtDNA escape
rates between cells bearing empty plasmid or cDNA of the GDAP1 m1, m3, m4, m6, m7, and m8
variants. Altogether, these results show that although the expression of GDAP1 does not affect the
growth of yeast cells, it does affect their physiology, in this instance the mitochondria. The changes
are so extensive that they can be observed. This supports the idea of using a yeast model to study
pathologies caused by mutations in the GDAP1 gene.
An altered morphology of mitochondria is often associated with a defective respiratory
function [32]. We asked whether the observed changes in the morphology of mitochondria translate
into the ability to grow on a non-fermentable carbon source, the conditions requiring functional
mitochondrial respiration. The expression of wild type GDAP1 caused a significant increase in the
number of cells which are unable to grow on non-fermentable carbon source containing media (p < 0.05)
and thus are respiratory deficient (Figure 3C). This effect was significantly reduced when GDAP1
m1, m2, m6, and m7 variants were expressed (p < 0,05) and was not altered by GDAP1 m3, m4,
and m5 variants (Figure 3C). The decrease in the number of respiratory deficient cells between yeast
transformants expressing different pathogenic GDAP1 variants and the wild type GDAP1 reflects the
influence of mutations on GDAP1 protein function connected with the observed phenotype.
3.6. The Expression of Human Wild-Type GDAP1 Gene Reduces the Growth Defect of the csg2 Mutant
Yeast Strain
The yeast-based model of the CMT4A disease that is obtained through the heterologous expression
of the cDNA of GDAP1 and its eight mutants represents a stable and functional system which has
several limitations. The main limitation lies in the mutation-specific phenotype. In essence, only
some GDAP1 mutations may be analyzed using the mtDNA escape assay. Similarly, the phenotypes
based upon colocalization of the GDAP1 with mitochondria are only suitable to distinguish whether
mutations affect the transmembrane domain of GDAP1. To obtain a simple model to use as a potential
platform for further drug screening, we looked for a repeatable growth phenotype.
Based on GDAP1 localization data obtained from the literature, on the abnormalities described as
being associated with GDAP1 mutations and on data from studies of other genes in which mutations
also cause CMT disease, we expressed the cDNA of GDAP1 in several specifically selected yeast
deletion mutants. We assumed that we should be able to find a mutant and/or conditions which
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allow us to monitor GDAP1 expression in simple growth test. One of our candidates was csg2∆
mutant, with the deletion of a gene required for mannosylation of inositolphosphorylceramide. This
mutant has higher levels of reactive oxygen species (ROS) and loss of mitochondrial DNA suppress
this accumulation [33]. Thus, we suspected that expression of GDAP1 or its variants which results
accumulation of Rho- cells could be helpful for growth of csg2∆ at stress conditions. We found that
the tunicamycin and calcium ion (Ca2+) sensitivity of the csg2∆ strain is suppressed by expression of
wild-type the GDAP1 allele (Figure 4A). The truncated version of GDAP1 protein (GDAP1 m1) and the
mutation in which localization to the mitochondria is perturbed (GDAP1 m2) were not able to restore
the normal growth of mutant cells on either plates containing tunicamycin or Ca2+ ions. Similar to
GDAP1 m1, the expression of GDAP1 m3 was unable to restore growth of the csg2∆ cells in either test
condition. The expression of GDAP1 m5, m6, and m7 restored the growth of the csg2∆mutant to a lesser
degree; weaker when compared to the wild-type GDAP1 but stronger than GDAP1 m1. In these terms
the mutations GDAP1 m1, m2, m3, m5, m6, m7, and m8 could be classified as loss-of-function or partial
loss-of-function mutations. Interestingly in this assay the effect of the Glu222Lys substitution caused
by the GDAP1 m4 mutation was negligible and the growth of the csg2∆ mutant expressing GDAP1
m4 was fully restored on tunicamycin and restored to a slightly lesser extent on Ca2+ ion containing
medium, in comparison to wild-type GDAP1 expression (Figure 4A). The lack of complementation by
some GDAP1 variants is not due to lack of protein expression as shown by Western blot analysis of
GDAP1 proteins (Figure 4B). In summary, our study has identified a new phenotype connected with
expression of the GDAP1 cDNA in yeast cells. This supported our hypothesis that we should be able
to identify conditions under which the presence of GDAP1 protein can be studied in a simple growth
assay. This test may help to identify at least some of the loss-of-function alleles found in patients.
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to OD600 ≈ 1. Ten-fold serial ilutions were prepared and spotted on YPD media containing 0.5 µg/mL
tunicamycin (Tm) or 0.5 M calcium chloride (CaCl2). Plates were incubated for 2 d (YPD and + Tm) or
6 d ( CaCl2) at 28 ◦C. (B) The csg2∆ yeast strain harboring empty vector ([-]) or plasmids with GDAP1
alleles (as indicated) were cultured overnight in SC-l u medium at 28 ◦C. Cells were then harvested
and disrupted. Total cell extracts were analyzed by SDS-PAGE, followed by immunoblotting with
anti-GDAP1 or anti-Histone H3 antibodies. Histone H3 was used as a loading control.
4. Discussion
One of the main problems faced by modern medical genetics is the proper identification of a
causative mutation followed by determination of the degree of pathogenicity in order to predict the
progress of the disease. Furthermore, most genetic disorders are rare, making them very difficult
to understand and ultimately to find treatment. It is also extremely expensive to develop efficient
treatments for such diseases. These problems also apply to the vast majority of the neurodegenerative
heritable disorders. Studies of therapies for neurodegenerative disorders are underdeveloped, even on
the preclinical level. In the present study we used, for the first time, a yeast-based model to establish a
system in which to assess the pathogenic effect of GDAP1 gene mutations.
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More than 15 years of studies have been devoted to the analysis of GDAP1 mutations. There are
some well documented variants such as the GDAP1 m5 (Leu239Phe) mutation reported in numerous
patients. However, several mutations are poorly documented. For example, the GDAP1 m6 (His123Arg)
mutation was found only in two families. Thus, testing of pathogenicity is even more necessary in
instances such as the GDAP1 m6 variant [23,24]. Even more interesting, and underexplored is the
pathogenic status of the GDAP1 m4 (Glu222Lys) mutation. The GDAP1 m4 mutation has been shown
by us to segregate with an extremely mild phenotype in the case of autosomal dominant CMT but in
combination with the GDAP1 m5 (Leu239Phe) mutation it causes severe CMT with autosomal recessive
traits [26]. Interestingly, out of the mutations with no clear phenotype in the yeast growth reduction
assay, it was the recurrent and pathogenic GDAP1 m5 mutation that resulted in the highest observed
level of mtDNA escape. This may indicate a separate and specific mechanism of action for the GDAP1
m5 mutation. The GDAP1 m8 (Ala156Gly) mutation, which segregates with a CMT with dominant
inheritance traits and a moderate clinical pathology, also results in a moderate pathogenic effect in
our yeast growth assay. In our study, the GDAP1 m4 (Glu222Lys) mutation has the lowest pathogenic
effect (Table 2). Although our previous results showed a clear segregation of the GDAP1 m4 variant
with two CMT phenotypes, its presence has only been documented in two families. There is still a
possibility that considering the small group of samples, the association of the GDAP1 m4 variant with
the CMT4A phenotype may be random. Thus, we cannot exclude the possibility that the GDAP1 m4
variant may be categorized as a harmless polymorphism.
Table 2. Pathogenic effect of GDAP1 gene mutations.
GDAP1
Variant (aa
Substitution)
Localization
Inheritance
of GDAP1
Mutation
Petite mtDNA
Escape
Effect on csg2∆ Summarized
Effect in Yeast
Clinical
PhenotypeTm CaCl2
GDAP1 M _ 12 - + + _ _
GDAP1 m1
(∆C-terminus) C AR 4 - - - strong severe
GDAP1 m2
(Gly327Asp) C AR 5 moderate - - strong severe
GDAP1 m3
(Glu218Glu) M AR 11 - - -
strong/
moderate
moderate to
severe
GDAP1 m4
(Glu222Lys) M AR/AD 9 minimal + + weak weak to moderate
GDAP1 m5
(Leu239Phe) M AR 10 maximal -/+ -/+ moderate
moderate in
homozygote, lack
in heterozygote
GDAP1 m6
(His123Arg) M AD 5 - -/+ -/+ weak weak
GDAP1 m7
(Met116Thr) M AR 5 - -/+ -/+ weak
moderate in
homozygote
GDAP1 m8
(Ala156Gly) M AD 6 - - -/+ moderate
moderate in
heterozygote
The summarized results illustrating the pathogenic effect of GDAP1 versions analyzed on selected phenotypes in
yeast in comparison to the clinical effect. Localization: C-cytoplasmic, M-mitochondrial; Inheritance AR—autosomal
recessive, AD—autosomal dominant; Petite—the results show the percentage of small colonies in the cells expressing
GDAP1 variants; mt DNA escape —the effect of the GDAP1 variants expression on a rate of mitochondrial DNA
escape reported as maximal, moderate or minimal; effect of GDAP1 variants expression on the csg2∆ mutant ability
to grow on media containing tunicamycin (Tm) or calcium chloride (CaCl2) (+) strong, (+/-) moderate, or (-) no effect.
Finally, our study confirms hypothesis that the GDAP1 mutations located within the
transmembrane domain result the severest phenotypes. These mutations lead to the mislocalization of
the GDAP1 protein to the cytoplasm instead of to the mitochondrial membrane [25]. In the present
study we have shown these types of GDAP1 gene mutations are also associated with the strongest
pathogenic effect. This observation is in accordance with previous clinical studies reporting extremely
severe phenotypes associated with Glu163X, Ser194X, Thr288fsx290, and Gly327Asp GDAP1 gene
mutations. The patients harboring these mutations become wheelchair-dependent during infancy
or early adulthood [8,25]. We propose that because the localization of the GDAP1 protein to the
mitochondrial membrane is critical for its function, the testing of GDAP1 location should be the
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first step in diagnosing the severity of a mutation, especially for mutations affecting the amino acid
sequence of the TMD. Furthermore, due to the observed heterogeneity in the mechanisms by which
GDAP1 mutations act, the tests used to assess their pathogenicity should be based upon the biological
properties/parameters summarized in Table 2.
The model established here is shown to be suitable for validating the pathogenic effect of known
GDAP1 mutations. Our system seems to be particularly suited for the validation of new sequence
GDAP1 variants identified in single patients manifesting with CMT. The ability to test in a simple
yeast-based model is attractive due to its ease of use and low cost. Even when the CMT phenotype has
been narrowed by careful clinical and electrophysiological assessment, the whole exome sequencing
approach (WES) may generate an average of 2 or 3 variants within CMT genes with ambiguous
pathogenic effect [2]. In this instance, access to a reproducible platform for functional studies may be a
necessary and useful tool for assessing the causative role of a certain CMT sequence variant.
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Appendix A
Table A1. The primer sequences for site directed mutagenesis.
Primer Name Primer Sequence
GDAP1 m2: c.980G>A;
p.Gly327Asp
GDAP1m2F 5′-cactcctgcaagcaaatcaaccacaagggtcgt-3′
GDAP1m2R 5′-acgacccttgtggttgatttgcttgcaggagtg-3′
GDAP1 m3: c.652C>G
p.Gln218Glu
GDAP1m3F 5′-caattcagtttcaacctcatccaagactttctccaactc-3′
GDAP1m3R 5′-gagttggagaaagtcttggatgaggttgaaactgaattg-3′
GDAP1 m4: c.664G>A
p.Glu222Lys
GDAP1m4F 5′-ttcttcatttcttctttgcaatttagtttcaacctgatccaagactt-3′
GDAP1m4R 5′-agtcttggatcaggttgaaactaaattgcaaagaagaaatgaagaa-3′
GDAP1 m5: c.715C>T
p.Leu239Phe
GDAP1m5F 5′-ggattcaccgcagaaccaaggttgctggc-3′
GDAP1m5R 5′-gccagcaaccttggttctgcggtgaatcc-3′
GDAP1 m6: c.368A>G
p.His123Arg
GDAP1m6F 5′-gcagctctcggtaacgttgtacccgtggg-3′
GDAP1m6R 5′-cccacgggtacaacgttaccgagagctgc-3′
GDAP1 m7: c.347T>C
p.Met116Thr
GDAP1m7F 5′-gtacccgtgggtaatacgtgctttctttatcaggca-3′
GDAP1m7R 5′-tgcctgataaagaaagcacgtattacccacgggtac-3′
GDAP1 m8: c.467C>G
p.Ala156Gly
GDAP1m8F
GDAP1m8R
5′-tacgaatccttgtagttccataagccgggatcatg-3′
5′-catgatcccggcttatggaactacaaggattcgta-3′
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Figure A1. Yeast wild-type cells transformed with plasmid encoding mitochondrially targeted green 
fluorescent protein (mt-GFP) and with empty vector ([-]) or plasmids encoding GDAP1 alleles (as indicated) 
were grown in SC-leu-his medium overnight and were then were shifted to glycerol-containing medium 
for 4 h to induce expansion of mitochondria. Cells were fixed, stained, and observed using confocal 
microscopy. GDAP1 was visualized by immunostaining (red), mitochondria using the mt-GFP protein 
marker (green) and the nucleus was stained with DAPI (blue). Scale bar 5 µm. 
Figure A1. Yeast wild-type cells transformed with plasmid encoding mitochondrially targeted
green fluorescent protein (mt-GFP) and with empty vector ([-]) or plasmids encoding GDAP1
alleles (as indicated) were grown in SC-leu-his medium overnight and were then were shifted to
glycerol-containing medium for 4 h to induce expansion of mitochondria. Cells were fixed, stained, and
observed using confocal microscopy. GDAP1 was visualized by immunostaining (red), mitochondria
using the mt-GFP protein marker (green) and the nucleus was stained with DAPI (blue). Scale bar
5 µm.
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